Newsletter | September 19, 2019

09.19.19 -- What These 2 Policies Mean For Biosimilars

 
Featured Editorial
A Bite-Sized Analysis Of The PDPRA For Biosimilar Makers
 
By Anna Rose Welch, editor, Biosimilar Development

In light of all the noise surrounding this Act, I reached out to reimbursement policy guru and Biosimilar Development editorial board member extraordinaire, Molly Burich. Here, she shares her initial thoughts on how several proposed changes to alter reimbursement under Medicare Part B and D could play out in the biosimilar space should the bill be made law.  

2 Bills, 1 Goal: Lower Drug Prices Through Biosimilars
 
By Ronald W. Lanton III

This article examines two Congressional bills aimed at increasing biosimilar utilization in an effort to lower drug costs: the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act and The Prescription Drug Pricing Reduction Act (PDPRA) of 2019.

Stakeholders To Gather In D.C. To Discuss U.S. Biosimilar Market’s Future
 
By Anna Rose Welch, editor, Biosimilar Development

Prior to the DIA Biosimilars Conference, I wanted to catch up with speaker Julie Reed of Pfizer to see what she’s most excited about imparting to attendees and what she hopes to learn from the upcoming conference.

Industry Insights
Chasing The Biopharma Market
E-Book | GE Healthcare Life Sciences

From new customer bases and vaccines to biosimilars and antibodies: what are the emerging trends and hot topics in biopharma, and how can companies take advantage of them in order to succeed?

How Services Marketers Can Own Their Performance Measures
Article | By Kevin Olson, Industry Standard Research

Service marketers can take control of their marketing performance by implementing credible marketing effectiveness measures and creating their own narrative.

Solutions
MabSelect Xtra
GE Healthcare Life Sciences
Connect With Biosimilar Development:
      Twitter